Connect Biopharma Holdings (NASDAQ:CNTB) saw its stock rise 8% on Wednesday after the company announced that it has completed enrollment in the Phase 2 Seabreeze STAT Asthma study. The trial is testing rademikibart, an anti-interleukin-4-receptor alpha antibody, as an adjunct to standard of care for acute exacerbations in patients with asthma and type 2 inflammation.
The company also indicated it remains on track to complete enrollment in its Seabreeze STAT COPD study this month. Connect Biopharma said topline results from the Phase 2 Seabreeze STAT Asthma study are anticipated in early September 2026, with findings from the COPD study to follow after that readout.
Rademikibart is being evaluated specifically for use alongside existing standard-of-care treatments to address acute exacerbations in asthma patients. Following the planned Phase 2 data releases, the company intends to meet with the U.S. Food and Drug Administration later this year to seek agreement on the design and path forward for a Phase 3 program, contingent on the Phase 2 outcomes and regulatory discussions.
On the corporate finance front, Connect Biopharma reported a strong balance sheet and said its cash resources provide a runway into the second half of 2027. The company described its strategic focus as developing therapies for inflammatory diseases.
The sequence of events laid out by the company - completion of Phase 2 asthma enrollment, near-term completion of COPD enrollment, a topline asthma readout in early September 2026, and a subsequent FDA meeting - establishes a clear near- to medium-term clinical calendar for investors and stakeholders. These milestones come into play alongside the firm’s reported financial runway, which frames the timing of future development and regulatory activities.
Context and implications
For market participants, the enrollment completion and upcoming data readout are clinical catalysts that have translated into immediate share-price movement. The developments are relevant to the biotechnology and broader healthcare sectors, particularly investors tracking clinical-stage companies advancing immunomodulatory therapies for inflammatory indications.
What the company has stated
- Enrollment for the Phase 2 Seabreeze STAT Asthma trial is complete.
- Enrollment for the Seabreeze STAT COPD trial is on track to finish this month.
- Topline asthma data expected in early September 2026, with COPD results to follow.
- Plans to meet the U.S. Food and Drug Administration later this year to gain alignment on a Phase 3 program after the Phase 2 readouts.
- Reported cash runway extends into the second half of 2027.
Bottom line
Connect Biopharma’s announcement marks a sequence of near-term operational and regulatory steps: completed Phase 2 asthma enrollment, imminent completion of COPD enrollment, a scheduled topline readout in early September 2026, and a planned FDA meeting later in the year. The company’s stated cash runway into the second half of 2027 provides a financial context for progressing these programs through clinical and regulatory milestones.